Fig. 4

Tumour progression and bone invasion depend on Axin2 expression in tumour cells in vivo. a Tumour volume was predominantly decreased in mice injected with Axin2-knockdown cells compared to both HSC-2 (i) and CA9–22 control cells (ii). b In micro-CT imaging analysis revealed extensive osteolytic lesions in the calvaria from HSC-2^Mock or CA9–22^Mock cell-bearing mice compared to the related Axin2-knockdown cell-bearing mice (i-ii). c The area of the tumour-associated stroma was predominantly increased at the tumour-bone interface in CA9–22^Mock or HSC-2^Mock cell-bearing mice compared to the related Axin2-knockdown cell-bearing mice (i-ii) (original magnification, × 200; scale bar, 50 μm, T: tumour, S: stroma, B: Bone) (* p < 0.05)